Clarus and Frazier back a ‘backyard’ biotech team with $26.5M for epigenetics R&D – FierceBiotech
0
“The band behind FerroKin BioSciences, a pioneer of the virtual biotech model, has gotten back together to take a stab at epigenetics, raising $26.5 million from some A-list investors to develop new treatments for orphan diseases.
The new company, Imago BioSciences, is working up a preclinical program with the potential to treat some undisclosed blood disorders. Clarus Ventures led the biotech’s A round, joined by Frazier Healthcare, Amgen ($AMGN) Ventures and Merck ($MRK) Research Labs Venture Fund.”
From – FierceBiotech